Search

Author/Creator Chee, L.

1. P776: A PHASE 2, OPEN-LABEL, ASCENDING DOSE STUDY OF KER-050 FOR THE TREATMENT OF ANEMIA IN PATIENTS WITH VERY LOW, LOW, OR INTERMEDIATE RISK MYELODYSPLASTIC SYNDROMES. (23rd June 2022)

Authors:
Tan, S.; Arbelaez, A.; Chee, L.; Fong, C. Y.; Hiwase, D.; Kannourakis, G.; Kwan, J.; Liang, J.; Puliyayil, A.; Rose, H.; Ross, D.; Teh, T.-C.; Westerman, D.; Wight, J.; Feng, W.; Lachey, J.; McGinty, A.; Natarajan, H.; Rovaldi, C.; Cooper, S.
Journal:
HemaSphere
Issue:
Volume 6(2022)Supplement 3
Page Start:
671
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

2. S155: EFFICACY AND SAFETY RESULTS FROM ASCEMBL, A PHASE 3 STUDY OF ASCIMINIB VS BOSUTINIB IN PATIENTS WITH CHRONIC MYELOID LEUKEMIA IN CHRONIC PHASE AFTER ≥2 PRIOR TYROSINE KINASE INHIBITORS: WK 96 UPDATE. (23rd June 2022)

Authors:
Rea, D.; Hochhaus, A.; Mauro, M. J.; Minami, Y.; Lomaia, E.; Voloshin, S.; Turkina, A.; Kim, D.-W.; Apperley, J. F.; Cortes, J. E.; Abdo, A.; Fogliatto, L. M.; Kim, D. D. H; le Coutre, P.; Saussele, S.; Annunziata, M.; Hughes, T. P.; Chaudhri, N.; Chee, L.; García-Gutiérrez, V.
Journal:
HemaSphere
Issue:
Volume 6(2022)Supplement 3
Page Start:
56
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

Limit your search